MX2024007064A - Metodos de administracion de un modulador de hemoglobina. - Google Patents
Metodos de administracion de un modulador de hemoglobina.Info
- Publication number
- MX2024007064A MX2024007064A MX2024007064A MX2024007064A MX2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A MX 2024007064 A MX2024007064 A MX 2024007064A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hemoglobin
- modulator
- administering
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288377P | 2021-12-10 | 2021-12-10 | |
| US202263421524P | 2022-11-01 | 2022-11-01 | |
| US202263429376P | 2022-12-01 | 2022-12-01 | |
| PCT/US2022/052411 WO2023107697A1 (en) | 2021-12-10 | 2022-12-09 | Methods of administering a modulator of hemoglobin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007064A true MX2024007064A (es) | 2024-06-20 |
Family
ID=85108880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007064A MX2024007064A (es) | 2021-12-10 | 2022-12-09 | Metodos de administracion de un modulador de hemoglobina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041312A1 (https=) |
| EP (1) | EP4444285A1 (https=) |
| JP (1) | JP2024545496A (https=) |
| KR (1) | KR20240116826A (https=) |
| AU (1) | AU2022408097B2 (https=) |
| CA (1) | CA3241881A1 (https=) |
| IL (1) | IL312835A (https=) |
| MX (1) | MX2024007064A (https=) |
| TW (1) | TW202339732A (https=) |
| WO (1) | WO2023107697A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4727555A1 (en) * | 2023-06-13 | 2026-04-22 | Global Blood Therapeutics, Inc. | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| EP4337659A1 (en) * | 2021-05-14 | 2024-03-20 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
-
2022
- 2022-12-09 EP EP22847662.8A patent/EP4444285A1/en active Pending
- 2022-12-09 KR KR1020247023029A patent/KR20240116826A/ko active Pending
- 2022-12-09 CA CA3241881A patent/CA3241881A1/en active Pending
- 2022-12-09 JP JP2024533948A patent/JP2024545496A/ja active Pending
- 2022-12-09 MX MX2024007064A patent/MX2024007064A/es unknown
- 2022-12-09 US US18/717,181 patent/US20250041312A1/en active Pending
- 2022-12-09 WO PCT/US2022/052411 patent/WO2023107697A1/en not_active Ceased
- 2022-12-09 TW TW111147489A patent/TW202339732A/zh unknown
- 2022-12-09 AU AU2022408097A patent/AU2022408097B2/en active Active
- 2022-12-09 IL IL312835A patent/IL312835A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022408097B2 (en) | 2026-03-12 |
| TW202339732A (zh) | 2023-10-16 |
| KR20240116826A (ko) | 2024-07-30 |
| US20250041312A1 (en) | 2025-02-06 |
| CA3241881A1 (en) | 2023-06-15 |
| EP4444285A1 (en) | 2024-10-16 |
| AU2022408097A1 (en) | 2024-05-30 |
| IL312835A (en) | 2024-07-01 |
| JP2024545496A (ja) | 2024-12-09 |
| WO2023107697A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| CO6390117A2 (es) | Regimen de dosificación para un agonista de los receptores de s1p | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| CO2021018155A2 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| BR112022012126A2 (pt) | Compostos antelmínticos compreendendo uma estrutura quinolínica | |
| CL2017001275A1 (es) | Análogos ligados de urea sustituidos como moduladores de sirtuina | |
| CL2024002763A1 (es) | Dosificación no lineal de mirdametinib | |
| CO2022015630A2 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| AR089409A1 (es) | Agente de control de enfermedades de las plantas | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| MX2024007064A (es) | Metodos de administracion de un modulador de hemoglobina. | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| BR112021019876A2 (pt) | Inibidores de pde9 para tratar anemia falciforme | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| CL2022003435A1 (es) | Métodos de tratamiento del complejo de esclerosis tuberosa | |
| CU20210044A7 (es) | Pirazoles como moduladores de hemoglobina | |
| ECSP10010249A (es) | Tratamiento de cardiopatías usando -bloqueantes | |
| BR112022004809A2 (pt) | Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1 | |
| ECSP23088732A (es) | Moduladores de trex1 | |
| CU20130004A7 (es) | Agentes terapéuticos 976 | |
| MX2022000426A (es) | Telmisartan para el tratamiento de la hipertension en perros. | |
| MX2022003628A (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. | |
| CL2023000261A1 (es) | Métodos de tratamiento de la neuralgia del trigémino |